Ionis And Biogen Say Development Of BIIB105 Will Be Discontinued Based On Data From Phase 1/2 Study
Portfolio Pulse from Benzinga Newsdesk
Ionis Pharmaceuticals and Biogen have announced the discontinuation of the development of BIIB105 based on data from a Phase 1/2 study.
May 16, 2024 | 11:36 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Biogen has decided to discontinue the development of BIIB105 based on Phase 1/2 study data.
The discontinuation of BIIB105 development is likely to negatively impact Biogen's stock price in the short term as it indicates a setback in their product pipeline.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
NEGATIVE IMPACT
Ionis Pharmaceuticals, in collaboration with Biogen, has decided to discontinue the development of BIIB105 based on Phase 1/2 study data.
The discontinuation of BIIB105 development is likely to negatively impact Ionis Pharmaceuticals' stock price in the short term as it indicates a setback in their product pipeline.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100